Abstract
Obliterative bronchiolitis (OB) is the leading cause of lung allograft loss but no efficient treatment for OB is exists. Inflammation and subsequent smooth muscle cell proliferation are central in OB development, leading to gradual occlusion of bronchioles. We examined the possibility to treat OB by selective inhibition of vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptor tyrosine kinase activity in rat tracheal allografts with PTK787 and imatinib respectively.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
